$CDXC
ChromaDex Corp. Stock $cdxc

$cdxc Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024009380 Filed on March 06, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$22.15M	$21.20M	$83.57M
YoY Change	-1.79%	0.95%	15.99%
Cost Of Revenue	$8.697M	$8.259M	$32.79M
YoY Change	-3.77%	-8.03%	12.09%
Gross Profit	$13.46M	$12.94M	$50.78M
YoY Change	-0.46%	7.66%	18.65%
Gross Profit Margin	60.74%	61.04%	60.76%
Selling, General & Admin	$12.09M	$11.95M	$51.42M
YoY Change	-15.4%	-1.93%	-9.15%
% of Gross Profit	89.86%	92.34%	101.26%
Research & Development	$2.095M	$1.159M	$4.958M
YoY Change	75.61%	-9.38%	2.74%
% of Gross Profit	15.57%	8.96%	9.76%
Depreciation & Amortization	$178.0K	$216.0K	$870.0K
YoY Change	-21.93%	-18.18%	0.12%
% of Gross Profit	1.32%	1.67%	1.71%
Operating Expenses	$14.19M	$13.11M	$56.38M
YoY Change	-8.39%	-2.64%	-8.21%
Operating Profit	-$731.0K	-$168.0K	-$5.599M
YoY Change	-62.86%	-88.37%	-69.94%
Interest Expense	$239.0K	$282.0K	$661.0K
YoY Change	262.12%	984.62%	21933.33%
% of Operating Profit
Other Income/Expense, Net		$0.00	$0.00
YoY Change			-100.0%
Pretax Income	-$492.0K	$114.0K	-$4.938M
YoY Change	-74.13%	-108.04%	-70.15%
Income Tax
% Of Pretax Income
Net Earnings	-$492.0K	$114.0K	-$4.938M
YoY Change	-74.13%	-108.04%	-70.15%
Net Earnings / Revenue	-2.22%	0.54%	-5.91%
Basic Earnings Per Share	-$0.01		-$0.07
Diluted Earnings Per Share	-$0.01	$0.00	-$0.07
COMMON SHARES
Basic Shares Outstanding	75.31M shares	75.12M shares	74.99M shares
Diluted Shares Outstanding	75.23M shares		74.99M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.57M	$27.17M	$27.17M
YoY Change	19.91%	34.25%	34.25%
Cash & Equivalents	$27.40M	$27.20M
Short-Term Investments
Other Short-Term Assets	$2.312M	$2.602M	$2.602M
YoY Change	-5.52%	-17.84%	-17.84%
Inventory	$12.50M	$14.53M	$14.53M
Prepaid Expenses
Receivables	$6.604M	$2.434M	$2.434M
Other Receivables	$0.00	$2.800M	$2.800M
Total Short-Term Assets	$48.98M	$49.53M	$49.53M
YoY Change	5.18%	6.37%	6.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.226M	$4.537M	$4.537M
YoY Change	-30.04%	-28.23%	-28.23%
Goodwill
YoY Change
Intangibles	$472.0K	$510.0K
YoY Change	-25.08%	-23.99%
Long-Term Investments
YoY Change
Other Assets	$405.0K	$383.0K	$383.0K
YoY Change	-23.87%	-22.94%	-22.94%
Total Long-Term Assets	$5.103M	$5.430M	$5.430M
YoY Change	-29.15%	-27.5%	-27.5%
TOTAL ASSETS
Total Short-Term Assets	$48.98M	$49.53M	$49.53M
Total Long-Term Assets	$5.103M	$5.430M	$5.430M
Total Assets	$54.08M	$54.96M	$54.96M
YoY Change	0.58%	1.68%	1.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.899M	$10.23M	$10.23M
YoY Change	-11.75%	5.71%	5.71%
Accrued Expenses	$10.47M	$9.493M	$10.18M
YoY Change	21.54%	29.39%	27.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.00K	$11.00K	$11.00K
YoY Change	-35.29%	-31.25%	-31.25%
Total Short-Term Liabilities	$19.45M	$20.62M	$20.62M
YoY Change	5.59%	15.41%	15.41%
LONG-TERM LIABILITIES
Long-Term Debt	$9.000K	$12.00K	$12.00K
YoY Change	-55.0%	-45.45%	-45.45%
Other Long-Term Liabilities	$5.667M	$5.874M	$5.874M
YoY Change	-22.45%	-21.62%	-21.62%
Total Long-Term Liabilities	$5.676M	$5.886M	$5.886M
YoY Change	-22.54%	-21.69%	-21.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.45M	$20.62M	$20.62M
Total Long-Term Liabilities	$5.676M	$5.886M	$5.886M
Total Liabilities	$25.13M	$26.51M	$26.51M
YoY Change	-2.42%	4.42%	4.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$191.0M	-$190.5M
YoY Change	1.88%	2.68%
Common Stock	$75.00K	$75.00K
YoY Change	1.35%	1.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.95M	$28.46M	$28.46M
YoY Change
Total Liabilities & Shareholders Equity	$54.08M	$54.96M	$54.96M
YoY Change	0.58%	1.68%	1.68%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$492.0K	$114.0K	-$4.938M
YoY Change	-74.13%	-108.04%	-70.15%
Depreciation, Depletion And Amortization	$178.0K	$216.0K	$870.0K
YoY Change	-21.93%	-18.18%	0.12%
Cash From Operating Activities	$300.0K	$649.0K	$7.100M
YoY Change	-89.29%	-297.87%	-147.02%
INVESTING ACTIVITIES
Capital Expenditures	$41.00K	$21.00K	$148.0K
YoY Change	-54.95%	-87.79%	-55.69%
Acquisitions
YoY Change
Other Investing Activities		-$5.000K	$5.000K
YoY Change
Cash From Investing Activities	-$41.00K	-$21.00K	-$143.0K
YoY Change	-54.95%	-87.79%	-57.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$14.00K	-76.00K	-$90.00K
YoY Change	1300.0%	-100.99%	-101.18%
NET CHANGE
Cash From Operating Activities	$300.0K	649.0K	$7.100M
Cash From Investing Activities	-$41.00K	-21.00K	-$143.0K
Cash From Financing Activities	-$14.00K	-76.00K	-$90.00K
Net Change In Cash	$240.0K	552.0K	$6.884M
YoY Change	-91.11%	-92.31%	-188.51%
FREE CASH FLOW
Cash From Operating Activities	$300.0K	$649.0K	$7.100M
Capital Expenditures	$41.00K	$21.00K	$148.0K
Free Cash Flow	$259.0K	$628.0K	$6.952M
YoY Change	-90.44%	-225.6%	-145.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001386570
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37752
CY2023	dei	Entity Registrant Name EntityRegistrantName	CHROMADEX CORPORATION
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2940963
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	10900 Wilshire Blvd
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90024
CY2023	dei	City Area Code CityAreaCode	310
CY2023	dei	Local Phone Number LocalPhoneNumber	388-6706
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	CDXC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	81100000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	75309118	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27325000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20441000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	68000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	122000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	14525000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	14677000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2450000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2967000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	49534000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	46567000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2137000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2799000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	510000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	671000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2400000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3523000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	383000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	497000	usd
CY2023Q4	us-gaap	Assets Assets	54964000	usd
CY2022Q4	us-gaap	Assets Assets	54057000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10232000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9679000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9493000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7337000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	691000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	680000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	11000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	16000	usd
CY2023Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	195000	usd
CY2022Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	157000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20622000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17869000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3311000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3955000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2563000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3539000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	12000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	22000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	26508000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	25385000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74981000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74981000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74567000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74567000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	75000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	74000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	218845000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	214094000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190460000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185493000	usd
CY2023Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-4000	usd
CY2022Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-3000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	28456000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	28672000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54964000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54057000	usd
CY2023	us-gaap	Revenues Revenues	83570000	usd
CY2022	us-gaap	Revenues Revenues	72050000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	32790000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	29253000	usd
CY2023	us-gaap	Gross Profit GrossProfit	50780000	usd
CY2022	us-gaap	Gross Profit GrossProfit	42797000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	28313000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24983000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	56379000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	61425000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5599000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18628000	usd
CY2023	cdxc	Other Income Net Employee Retention Credit Cares Act OtherIncomeNetEmployeeRetentionCreditCARESAct	0	usd
CY2022	cdxc	Other Income Net Employee Retention Credit Cares Act OtherIncomeNetEmployeeRetentionCreditCARESAct	2085000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	661000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4938000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16540000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74985000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74985000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69729000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69729000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	31727000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	400000	usd
CY2022	cdxc	Issuance Of Common Stock Net Of Offering Costs Amount IssuanceOfCommonStockNetOfOfferingCostsAmount	7747000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5739000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-1000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16540000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	28672000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4751000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-1000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4938000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	28456000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4938000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16540000	usd
CY2023	us-gaap	Depreciation Depreciation	870000	usd
CY2022	us-gaap	Depreciation Depreciation	869000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	158000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	186000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	677000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	829000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4751000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	5739000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	5000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	964000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	63000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-75000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-67000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2255000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	3319000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-152000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1076000	usd
CY2023	cdxc	Implementation Costs For Cloud Computing Arrangement ImplementationCostsForCloudComputingArrangement	60000	usd
CY2022	cdxc	Implementation Costs For Cloud Computing Arrangement ImplementationCostsForCloudComputingArrangement	304000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-631000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	872000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	553000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-744000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2156000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	856000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-644000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-391000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	38000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-519000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-463000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7117000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15098000	usd
CY2023	cdxc	Purchases Of Leasehold Improvements And Equipment PurchasesOfLeaseholdImprovementsAndEquipment	148000	usd
CY2022	cdxc	Purchases Of Leasehold Improvements And Equipment PurchasesOfLeaseholdImprovementsAndEquipment	334000	usd
CY2023	cdxc	Proceeds From The Sale Of Leasehold Improvements And Equipment Net ProceedsFromTheSaleOfLeaseholdImprovementsAndEquipmentNet	5000	usd
CY2022	cdxc	Proceeds From The Sale Of Leasehold Improvements And Equipment Net ProceedsFromTheSaleOfLeaseholdImprovementsAndEquipmentNet	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-143000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-334000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7747000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	75000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	77000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	15000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	16000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-90000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7654000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6884000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7778000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20441000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28219000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27325000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20441000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	610000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	507000	usd
CY2023	cdxc	Right Of Use Assets And Operating Lease Liabilities Reduced For Entering Into Lease Amendment RightOfUseAssetsAndOperatingLeaseLiabilitiesReducedForEnteringIntoLeaseAmendment	446000	usd
CY2022	cdxc	Right Of Use Assets And Operating Lease Liabilities Reduced For Entering Into Lease Amendment RightOfUseAssetsAndOperatingLeaseLiabilitiesReducedForEnteringIntoLeaseAmendment	0	usd
CY2023	cdxc	Finance Lease Obligation Incurred For Purchase Of Computer Equipment And Software FinanceLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware	0	usd
CY2022	cdxc	Finance Lease Obligation Incurred For Purchase Of Computer Equipment And Software FinanceLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware	34000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4958000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24983000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	56379000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5599000	usd
CY2022	us-gaap	Revenues Revenues	72050000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	29253000	usd
CY2022	us-gaap	Gross Profit GrossProfit	42797000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	28313000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4826000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex International, Inc., ChromaDex Analytics, Inc., ChromaDex Asia Limited, Asia Pacific Scientific, Inc., ChromaDex Europa B.V. and ChromaDex Sağlik Ürünleri Anonim Şirketi (collectively, “ChromaDex” or the “Company”) are a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ChromaDex is the innovator behind the NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent and/or licensed rights portfolio. The Company delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen®. The Company further develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. Additionally, the Company offers natural product fine chemicals, known as phytochemicals, and related research and development services.</span></div>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Accounting Estimates</span>: The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3300000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	4000000	usd
CY2023	cdxc	Shipping And Handling Fees ShippingAndHandlingFees	567000	usd
CY2022	cdxc	Shipping And Handling Fees ShippingAndHandlingFees	428000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	17700000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	10500000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	152000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and cash equivalents and trade receivables. Cash and cash equivalents, consist of bank deposits </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and short-term investments, including low-risk, fixed-income investments and highly liquid investment-grade debt instruments with an original maturity of three months or less. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains several bank accounts for its operations primarily at three financial institutions in the U.S. and one financial institution in Hong Kong. The Company’s U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 at each institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. Notably, the Company engages in a sweep service with the U.S. institution holding the largest portion of the Company's funds. This service conducts nightly transfers, ensuring that the Company's cash balances exceeding the FDIC limit are judiciously distributed to other reputable banking partners. These transfers are strategically executed in amounts below the FDIC threshold, thereby optimizing the Company's cash balance protection. The Company’s trade receivables are derived from sales to its customers. The Company assesses credit risk of its customers through quantitative and qualitative analysis. From this analysis, the Company establishes credit limits and manages the risk exposure. The Company, however, may from time-to-time incur credit losses due to bankruptcy or other failures from its customers to pay.</span></div>
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69729000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69729000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	589000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	650000	shares
CY2023	cdxc	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	174000	shares
CY2022	cdxc	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	183000	shares
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	10300000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	11400000	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	reportable_segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	reportable_segment
CY2023	us-gaap	Revenues Revenues	83570000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	32790000	usd
CY2023	us-gaap	Gross Profit GrossProfit	50780000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	26438000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4900000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7100000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27200000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4938000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16540000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74985000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74985000	shares
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28286000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	61425000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18628000	usd
CY2023	us-gaap	Revenues Revenues	83570000	usd
CY2022	us-gaap	Revenues Revenues	72050000	usd
CY2023	us-gaap	Proceeds From Customers ProceedsFromCustomers	25000000.0	usd
CY2022	us-gaap	Proceeds From Customers ProceedsFromCustomers	21800000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	964000	usd
CY2023Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	15900000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	3000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	510000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5962000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7901000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3537000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2992000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4478000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3284000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	548000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	500000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	14525000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	14677000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1849000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2318000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	510000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	671000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	158000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	186000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	151000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	151000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	151000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	42000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	12000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	7547000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	7353000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	5410000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	4554000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2137000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2799000	usd
CY2023	us-gaap	Depreciation Depreciation	870000	usd
CY2022	us-gaap	Depreciation Depreciation	869000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	5000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	355000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	355000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1000000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1200000	usd
CY2023	cdxc	Lessee Operating Lease Number Of Extension Options LesseeOperatingLeaseNumberOfExtensionOptions	1	extension_option
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2400000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3500000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3300000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4200000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	905000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	941000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	293000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	176000	usd
CY2023	cdxc	Total Operating Lease Expenses TotalOperatingLeaseExpenses	1198000	usd
CY2022	cdxc	Total Operating Lease Expenses TotalOperatingLeaseExpenses	1117000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	16000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	164000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1214000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1281000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	832000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1135000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	901000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	491000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	358000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	30000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3747000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	493000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3254000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	691000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2563000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.754
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.764
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.023
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q4	us-gaap	Share Price SharePrice	1.43
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.108
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.032
CY2023	cdxc	Change In State Tax Rate ChangeInStateTaxRate	0.003
CY2022	cdxc	Change In State Tax Rate ChangeInStateTaxRate	-0.003
CY2023	cdxc	Effective Income Tax Rate Reconciliation Tax Expirations Of Net Operating Losses EffectiveIncomeTaxRateReconciliationTaxExpirationsOfNetOperatingLosses	-0.003
CY2022	cdxc	Effective Income Tax Rate Reconciliation Tax Expirations Of Net Operating Losses EffectiveIncomeTaxRateReconciliationTaxExpirationsOfNetOperatingLosses	0.016
CY2023Q4	us-gaap	Share Price SharePrice	1.43
CY2023Q4	us-gaap	Share Price SharePrice	1.43
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4751000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	5739000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3500000	usd
CY2022	cdxc	Supply Commitment Milestone Payment SupplyCommitmentMilestonePayment	0	usd
CY2023	cdxc	Supply Commitment Milestone Payment SupplyCommitmentMilestonePayment	0	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	644000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	391000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3311000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3955000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.055
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.055
CY2023	cdxc	Effective Income Tax Rate Reconciliation Tax Change In Stock Options And Restricted Stock EffectiveIncomeTaxRateReconciliationTaxChangeInStockOptionsAndRestrictedStock	-0.127
CY2022	cdxc	Effective Income Tax Rate Reconciliation Tax Change In Stock Options And Restricted Stock EffectiveIncomeTaxRateReconciliationTaxChangeInStockOptionsAndRestrictedStock	-0.078
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.027
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.177
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.009
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36735000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37308000	usd
CY2023Q4	cdxc	Deferred Tax Assets Stock Options And Restricted Stock DeferredTaxAssetsStockOptionsAndRestrictedStock	4484000	usd
CY2022Q4	cdxc	Deferred Tax Assets Stock Options And Restricted Stock DeferredTaxAssetsStockOptionsAndRestrictedStock	4528000	usd
CY2023Q4	cdxc	Deferred Tax Assets Tax Interest Expense DeferredTaxAssetsTaxInterestExpense	0	usd
CY2022Q4	cdxc	Deferred Tax Assets Tax Interest Expense DeferredTaxAssetsTaxInterestExpense	258000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	343000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	410000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	18000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	32000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2194000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1654000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1666000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	922000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	878000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1050000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	99000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	60000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	105000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	104000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	227000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	185000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46749000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46511000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46391000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46254000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	358000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	257000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	358000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	257000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	358000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	257000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	100000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	46400000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	46300000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Gilti Amount EffectiveIncomeTaxRateReconciliationGiltiAmount	100000	usd
CY2023	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	75000	usd
CY2022	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	77000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	68000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	69000	usd
CY2023Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	15850000	usd
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	15850000	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	2100000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	2000000	usd
CY2019Q3	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	1600000	usd
CY2022Q3	cdxc	Other Income Net Employee Retention Credit Cares Act OtherIncomeNetEmployeeRetentionCreditCARESAct	2100000	usd
CY2023	cdxc	Proceeds From Employee Retention Tax Credit Cares Act ProceedsFromEmployeeRetentionTaxCreditCARESAct	900000	usd
CY2022	cdxc	Proceeds From Employee Retention Tax Credit Cares Act ProceedsFromEmployeeRetentionTaxCreditCARESAct	600000	usd
CY2023Q4	cdxc	Prepaid Expenses And Other Current Assets Employee Retention Credit Cares Act PrepaidExpensesAndOtherCurrentAssetsEmployeeRetentionCreditCARESAct	900000	usd
CY2023Q4	cdxc	Accrued Expenses Employee Retention Credit Cares Act AccruedExpensesEmployeeRetentionCreditCARESAct	-100000	usd
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-009380-index-headers.html	Edgar Link	pending
0001628280-24-009380-index.html	Edgar Link	pending
0001628280-24-009380.txt	Edgar Link	pending
0001628280-24-009380-xbrl.zip	Edgar Link	pending
cdxc-20231231.htm	Edgar Link	pending
cdxc-20231231.xsd	Edgar Link	pending
cdxc-20231231_g1.jpg	Edgar Link	pending
cdxc-20231231_g2.jpg	Edgar Link	pending
cdxc-20231231_g3.jpg	Edgar Link	pending
cdxc-20231231_g4.jpg	Edgar Link	pending
cdxc-20231231_cal.xml	Edgar Link	unprocessable
cdxc-20231231_def.xml	Edgar Link	unprocessable
cdxcq4202310kex231consent.htm	Edgar Link	pending
cdxcq4202310kexhibit311.htm	Edgar Link	pending
cdxcq4202310kexhibit312.htm	Edgar Link	pending
cdxcq4202310kexhibit321.htm	Edgar Link	pending
cdxcq42023ex211subsidiaries.htm	Edgar Link	pending
ex1024-10900wilshirechroma.htm	Edgar Link	pending
ex1060-amendedincentivecom.htm	Edgar Link	pending
ex971-doddxfrankclawbackpo.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_01.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
image_1a.jpg	Edgar Link	pending
image_2a.jpg	Edgar Link	pending
image_3a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
cdxc-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cdxc-20231231_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
storagespaceimage.jpg	Edgar Link	pending
cdxc-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXC
ChromaDex Corp. Stock $cdxc

2024 Q1 Form 10-K Financial Statement

#000162828024009380 Filed on March 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC ChromaDex Corp. Stock $cdxc

2024 Q1 Form 10-K Financial Statement

#000162828024009380 Filed on March 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC
ChromaDex Corp. Stock $cdxc